• Renal failure · Nov 1995

    Use of APACHE II classification to evaluate outcome and response to therapy in acute renal failure patients in a surgical intensive care unit.

    • E F van Bommel, N D Bouvy, W C Hop, H A Bruining, and W Weimar.
    • Department of Internal Medicine I, University Hospital Dijkzigt, Rotterdam, The Netherlands.
    • Ren Fail. 1995 Nov 1;17(6):731-42.

    AbstractThe study objective was to determine the applicability of the acute physiology and chronic health evaluation (APACHE) II score in surgical patients with acute renal failure (ARF) requiring dialytic support, and to assess its utility in evaluating data from this specific disease group. This was a retrospective, partly prospective follow-up study of patients who developed ARF during their course of stay on the surgical intensive care unit (ICU) of a Dutch university hospital from January 1, 1986, to January 31, 1994. A total of 111 patients were identified, of whom 104 patients were considered eligible for this study. Data for the individual APACHE II scores were calculated from the most deranged values during the initial 24 h of ICU admission (APACHE II1) and on the day dialytic support was instituted (APACHE II2). The ratio between the two APACHE II scores was also calculated for each patient (AP2/AP1 ratio). Receiver operating characteristic curves (ROC) were constructed. Other variables evaluated included age, sex, serum creatinine, diagnostic category, time from ICU admission to start of dialytic support, and the type of dialytic support. Of these 104 patients (median age 64; range 23-85 years), 51 (50%) survived to leave the ICU, of whom 47 (46%) survived to leave hospital. The APACHE II2 score (27.0 +/- 4.4 vs. 22.4 +/- 3.5; p < 0.001) and AP2/AP1 ratio (1.12 +/- 0.09 vs. 0.97 +/- 0.06; p < 0.001) were significantly higher for nonsurvivors as compared to survivors. The ROC curve was most discriminative for the AP2/AP1 ratio (area under the curve 0.92) and to a lesser extent for the APACHE II2 score (area under the curve 0.78). Estimated risk of death with the APACHE II equation did not improve predictive power. Multivariate analysis of various variables revealed the AP2/AP1 ratio as the single most important factor predicting death (odds ratio 13.8, p < 0.001). Adjusting for the AP2/AP1 ratio, no impact on outcome was observed for age, diagnostic category, time from ICU admission to start of dialytic support, and the type of dialytic support. Above a value of 1.0 of the AP2/AP1 ratio, logistic regression revealed a sharp increase in death probability with increasing AP2/AP1 ratio. APACHE II, when used at the time of initiation of dialytic support, proved to be a valid way in our surgical ICU to stratify ARF patients by the severity of their illness. Moreover, use of the AP2/AP1 ratio further improved the usefulness of this severity index and may help to identify patients who have little chance of survival. Predicting death with the APACHE II equation did not improve predictive power.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.